GTC Nails ATryn Deal With Ovation
This article was originally published in The Pink Sheet Daily
Executive Summary
Small payout now, but more may be due later, as the antithrombin goes up against sepsis and heparin resistance.
You may also be interested in...
FDA Advisors To Determine Need For Post-Marketing Study Of GTC Biotherapeutics’ ATryn
The antithrombin’s efficacy and safety profile suggest ATryn has a clear path to approval.
FDA Advisors To Determine Need For Post-Marketing Study Of GTC Biotherapeutics’ ATryn
The antithrombin’s efficacy and safety profile suggest ATryn has a clear path to approval.
GTC Completes BLA For Recombinant Clot Buster Atryn
Phase II study in sepsis DIC indication is actively enrolling, GTC says.